FY2022 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Reduced by Wedbush

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) – Research analysts at Wedbush lowered their FY2022 EPS estimates for shares of Catabasis Pharmaceuticals in a report released on Tuesday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings of $0.61 per share for the year, down from their previous forecast of $0.71. Wedbush currently has a “Outperform” rating and a $6.00 target price on the stock.

Catabasis Pharmaceuticals (NASDAQ:CATB) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.07. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million.

Separately, Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Friday, January 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Catabasis Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $5.18.

CATB stock traded down $0.11 during trading hours on Wednesday, reaching $1.92. The company’s stock had a trading volume of 394,145 shares, compared to its average volume of 1,057,294. Catabasis Pharmaceuticals has a twelve month low of $1.09 and a twelve month high of $3.78. The company has a market capitalization of $59.52, a price-to-earnings ratio of -1.58 and a beta of 0.80.

Institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its position in shares of Catabasis Pharmaceuticals by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 49,000 shares in the last quarter. Deutsche Bank AG purchased a new position in shares of Catabasis Pharmaceuticals in the fourth quarter valued at about $335,000. Renaissance Technologies LLC lifted its position in shares of Catabasis Pharmaceuticals by 167.2% in the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock valued at $698,000 after acquiring an additional 293,300 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Catabasis Pharmaceuticals by 146.1% in the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 45,476 shares in the last quarter. Institutional investors and hedge funds own 34.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3293732/fy2022-eps-estimates-for-catabasis-pharmaceuticals-inc-catb-reduced-by-wedbush.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Earnings History and Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ichor  Stock Price Up 8.7%
Ichor Stock Price Up 8.7%
MongoDB  Trading 7.1% Higher
MongoDB Trading 7.1% Higher
Intercept Pharmaceuticals  Trading Up 5.9%
Intercept Pharmaceuticals Trading Up 5.9%
Analysts Expect BB&T  Will Post Quarterly Sales of $2.91 Billion
Analysts Expect BB&T Will Post Quarterly Sales of $2.91 Billion
First Financial Bank  Receives $30.00 Consensus PT from Brokerages
First Financial Bank Receives $30.00 Consensus PT from Brokerages
Signature Bank  Given Consensus Recommendation of “Buy” by Brokerages
Signature Bank Given Consensus Recommendation of “Buy” by Brokerages


© 2006-2018 Ticker Report. Google+.